Business Context and Reporting Period
Company: ORAGENICS INC
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2004 (Event Date: March 29, 2004)
Reporting Period: Specific event disclosure regarding warrant exercises occurring prior to March 24, 2004.
Key Financial Metrics
This filing reports a specific capital event rather than comprehensive financial statements. Key metrics disclosed include:
- Cash Inflow: $2,986,200 received from warrant exercises.
- Warrants Exercised: 995,400 Series B warrants (representing 83% of the 1,200,000 outstanding).
- Exercise Price: $3.00 per warrant.
Note: The filing text does not provide clear values for revenue, profit, operating margins, total debt, or liquidity ratios beyond the specific cash inflow mentioned above.
Material Changes
The primary material change is the significant reduction in outstanding Series B warrants and the corresponding increase in cash assets. The exercise of 83% of the outstanding Series B warrants prior to their expiration date represents a major capitalization event for the period.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the warrant exercise but does not contain forward-looking guidance, strategic outlook, or specific risk factors within the text provided.
Unusual Items: The high percentage (83%) of warrants exercised immediately prior to expiration is noted as the central event of this report.
Investor Verification Checklist
- Verify the exact number of shares issued upon the exercise of 995,400 warrants.
- Confirm the updated total share count and potential dilution impact post-exercise.
- Review the attached Press Release (Exhibit 99.1) for any additional context on the use of proceeds.
- Check subsequent filings for the impact of this $2.99 million cash injection on the company's liquidity position.